Clinical Trial Update: Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial shows that the meningococcal vaccine GSK134612 is non-inferior to Mencevax in 11-17-year-olds.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK134612 (Meningococcal vaccine)
• Mencevax

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-04-02